Oncology

PTX-252 is a novel molecular drug designed to increase cancer cells' sensitivity to chemotherapy in the treatment of acute myeloid leukemia.

Significant study results could inform clinical practice strategies.

Presentations detail clinical trial results and focus on drugs in the pipeline.

The approval was based on the results of a phase 3 trial that found an improvement in progression-free survival among individuals treated with pembrolizumab.

2023 was an impactful year for the field of oncology pharmacy.

Biosimilars are proven to be highly similar to the original products with no clinical meaningful differences.

In addition to the current principles and treatment regimens, there are upcoming data on myelofibrosis drugs that could be reported as early as 2024.

Not only were individuals with BMIs of 30 and higher likely to have MGUS, but those who reported heavy smoking and short sleep were also more likely to have detectable levels of MGUS.

The separation between those who travel for care compared to those who go to the local hospital may drive inequalities in health care.

A majority of patients who received first-line chemotherapy switched to amivantamab-vmjw plus chemotherapy as second-line therapy.

A leukemia clinical pharmacy specialist delves into the significance of educating patients on treatments and serving as a resource for both patients and health care providers.

In addition, patients who were treated with liso-cel therapy had a higher average life expectancy and QALYs, compared to those who were treated with standard care.

The pharmacist can assist with managing drug interactions, patient education, therapy selection, physician education, and more.

Compared to standard of care TKIs, asciminib also presented favorable safety and tolerability profiles with fewer reported AEs among patients.

Individuals with ischemic stroke that resided in areas with an indoor radon concentration greater than 4 pCi/L had an increased risk of developing clonal hematopoiesis of indeterminate potential.

The accepted sBLA comes after phase 3 clinical trial results which demonstrated better overall survival, progression-free survival, and confirmed overall response rate than chemotherapy in patients with cervical cancer.

The study results also demonstrated isatuximab had safety and tolerability profiles that were consistent with other clinical trials.

In the ambulatory setting, oncology pharmacists independently prescribe medications to support and manage therapy toxicities for cancer patients.

The report allows management to provide guaranteed assessments throughout the screenings that could aid early detection, diagnosis, and lung cancer treatment.

Nearly 75% of patients who had an initial complete response with mosunetuzumab maintained that complete response after 3 years.

The prospective observational study assessed a 2-year increasing lung cancer diagnosis risk, lung cancer characteristics, and the overall survival between LNP and LDCT screening.

Eliminating certain factors within the GRN resulted in the network shutting down, potentially leading to cancer cell death due to an inability to replicate, according to the study authors.

New CAR T development method infuses immune T cells from healthy people into patients to improve outcomes.

This study showed the importance of a multidisciplinary team’s expertise to investigate a clinical inquiry beyond the scope of the clinicians’ skillset and their access to necessary technology.

There was no statistically significant difference between Lovenox (Sanofi–Aventis Pharmaceuticals, France) and biosimilar enoxaparin in the occurrence of post-operative thrombosis for digestive cancer.

Investigators found that those who used statins post-breast cancer diagnosis had a lower risk of breast cancer death when the median total cholesterol decreased.

The investigators advise that the use of bendamustine should be avoided when possible in patients with refractory LBCL who are potential candidates for CAR T-cell therapy.

In the Augment-101 phase 2 study, 63% of patients experienced overall response rate with revumenib.

This therapeutic could work for diseases of the B cell receptor signaling transduction pathway that do not respond well to single-agent BTK inhibitor.

According to the findings, the use of venetoclax, as well as other new therapies, improved overall survival from 28.6% to 45.3% in non-Hispanic Black patients with AML.